Oryzon Genomics SA (ORY)

Madrid
Currency in EUR
1.476
-0.044(-2.63%)
Closed
ORY Scorecard
Full Analysis
Analysts anticipate sales decline in the current year
Fair Value
Day's Range
1.4621.520
52 wk Range
1.4002.140
Key Statistics
Edit
Bid/Ask
1.476 / 1.48
Prev. Close
1.476
Open
1.52
Day's Range
1.462-1.52
52 wk Range
1.4-2.14
Volume
137.96K
Average Volume (3m)
133.96K
1-Year Change
-23.52%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
6.167
Upside
+317.80%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year
Show more

Oryzon Genomics SA Company Profile

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases. The company was founded in 2000 and is based in Cornellà de Llobregat, Spain.

Compare ORY to Peers and Sector

Metrics to compare
ORY
Peers
Sector
Relationship
P/E Ratio
−21.4x−3.1x−0.6x
PEG Ratio
−6.27−0.010.00
Price/Book
1.1x3.6x2.6x
Price / LTM Sales
6.2x19.1x3.1x
Upside (Analyst Target)
204.1%157.6%55.4%
Fair Value Upside
Unlock14.8%10.2%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.167

(+317.80% Upside)

FAQ

What Is the Oryzon Genomics (ORY) Stock Price Today?

The Oryzon Genomics stock price today is 1.476

What Stock Exchange Does Oryzon Genomics Trade On?

Oryzon Genomics is listed and trades on the Madrid stock exchange.

What Is the Stock Symbol for Oryzon Genomics?

The stock symbol for Oryzon Genomics is "ORY."

What Is the Oryzon Genomics Market Cap?

As of today, Oryzon Genomics market cap is 92.90M.

What is Oryzon Genomics Earnings Per Share?

The Oryzon Genomics EPS is -0.072.

What Is the Next Oryzon Genomics Earnings Date?

Oryzon Genomics will release its next earnings report on 02 Mar 2025.

From a Technical Analysis Perspective, Is ORY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.